Eyenovia Inc ( EYEN ) stock is trading higher on Thursday after its plunge yesterday, with a session volume of 6.7 million, versus an average volume of 1.33 as per data from Benzinga Pro.

On Wednesday, the ophthalmic technology company agreed to sell 12.85 million shares at $0.40 per share.

The aggregate gross proceeds to the company from the offering are expected to be approximately $5.14 million.

The company will use the net proceeds to fund commercialization activities for its products, Mydcombi and clobetasol propionate, to complete the CHAPERONE pediatric myopia clinical study and for working capital and general corporate purposes.

Proceeds may also be used to repay amounts outstanding under the company's loan and security agreement with Avenue Capital Management II, L.P., and related entities.

Mydcombi (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% is indicated for mydriasis, Clobetasol Propionate Ophthalmic Suspension, 0.05% for postsurgical inflammation and pain,

The company is developing the Optejet device for use in connection with its drug-device therapeutic product for pediatric progressive myopia and out-licensing for additional indications.

Price Action: EYEN stock is up 11.8% at $0.52 at last check Thursday.

Read Next:

Chinese EV Maker BYD Seeks State Incentives for New Mexico Plant Amid US Pressure: Report.

Don’t miss the opportunity to dominate in a volatile market at the Benzinga SmallCAP Conference on Oct. 9-10 at the Chicago Marriott Downtown Magnificent Mile. Get exclusive access to CEO presentations, 1:1 meetings with investors, and valuable insights from top financial experts. Whether you’re a trader, entrepreneur, or investor, this event offers unparalleled opportunities to grow your portfolio and network with industry leaders. Secure your spot and get your tickets today!